| ￥3300 | |
| Z05568-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its ability to inhibit carboxypeptidase A1 cleavage of the colorimetric peptide substrate AcPheThiapheOH in the presence of 5,5'Dithiobis (2nitrobenzoic acid) (DTNB). Test result meets the standard. | ||||
| Expression System | E.coli | ||||
| Theoretical Molecular Weight | 27.16 kDa | ||||
| Apparent Molecular Weight | The protein migrates to 30-35 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of Latexin, His, Human is greater than 95% as determined by SEC-HPLC. »
Latexin, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Latexin, the endogenous protein inhibitor of the A/B subfamily of metallocarboxypeptidases, is expressed in small nociceptive neurons in sensory ganglia and in a subset of neurons in the telencephalon. Recently, the latexin (Lxn) gene was identified as a potential tumor suppressor in several types of solid tumors and lymphoma, and Lxn expression was found to be absent or downregulated in leukemic cells. |
| Synonyms | ECI; MUM; TCI; LXN |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
